Over the last four years, life for multiple-sclerosis patients has changed for the better as a new generation of powerful oral drugs has moved into a market dominated by injectables. But things aren’t done changing yet, as a September conference in Boston showed. At the meeting, held jointly by the American and European Committees for Treatment and Research in MS, the star presentation came from small biotech Receptos (RCPT). The phase-two
Biotech Receptos (RCPT) shot up more than 14% in morning trading on the stock market today, just shy of an all-time high, after it released more good data from a mid-stage clinical trial of its multiple-sclerosis drug. Receptos filed a late-breaking abstract on the study of RPC1063 for the MS Boston conference on multiple sclerosis, which runs Wednesday through Sunday. It already revealed its initial findings on June 10, showing an 86% reduction
Receptos (RCPT) stock leapt 37% in massive volume to close at 39.94 in the stock market today, following Monday’s late announcement that its oral multiple-sclerosis drug RPC-1063 had reduced brain lesions in a phase-two clinical trial. RPC-1063 is chemically similar to Novartis’ (NVS) Gilenya, but Leerink analyst Marko Kozul wrote in a note Monday that the trial results “suggest it is meaningfully differentiated from Gilenya and other competing